Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s Why

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $8.6720, but opened at $8.33. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.33, with a volume of 415 shares.

Analyst Ratings Changes

A number of equities analysts have commented on SGIOY shares. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 2.0%

The firm’s 50-day moving average price is $9.30 and its 200 day moving average price is $9.89. The company has a current ratio of 1.58, a quick ratio of 1.46 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $14.50 billion, a price-to-earnings ratio of 10.65, a PEG ratio of 3.20 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.03. The business had revenue of $881.71 million for the quarter, compared to analyst estimates of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%. On average, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.